{"id":"travoprost-0-004-ophthalmic-solution","safety":{"commonSideEffects":[{"rate":"30-50","effect":"Conjunctival hyperemia"},{"rate":"10-25","effect":"Iris pigmentation increase"},{"rate":"10-20","effect":"Eyelash growth (hypertrichosis)"},{"rate":"5-15","effect":"Eye irritation/discomfort"},{"rate":"5-10","effect":"Foreign body sensation"}]},"_chembl":{"chemblId":"CHEMBL1200799","moleculeType":"Small molecule","molecularWeight":"500.55"},"_dailymed":{"setId":"00dc284f-fd96-423b-bb8f-b90ee13439bf","title":"TRAVOPROST OPHTHALMIC SOLUTION, 0.004% SOLUTION/ DROPS [MYLAN PHARMACEUTICALS INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Travoprost mimics the action of prostaglandin F by activating FP receptors on the ciliary muscle bundle and trabecular meshwork. This activation enhances drainage of aqueous humor through the unconventional uveoscleral pathway, reducing intraocular pressure. The drug is selective for FP receptors and does not significantly activate other prostaglandin receptors.","oneSentence":"Travoprost is a prostaglandin F analog that binds to prostaglandin F (FP) receptors in the eye to increase uveoscleral outflow of aqueous humor, thereby lowering intraocular pressure.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:13:56.522Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Open-angle glaucoma"},{"name":"Ocular hypertension"}]},"trialDetails":[{"nctId":"NCT06152861","phase":"PHASE2","title":"Travoprost Ophthalmic Topical Cream for Open-angle Glaucoma or Ocular Hypertension","status":"UNKNOWN","sponsor":"Glaukos Corporation","startDate":"2023-11-15","conditions":"Open Angle Glaucoma, Ocular Hypertension","enrollment":250},{"nctId":"NCT01444040","phase":"PHASE4","title":"Subjects With Open-angle Glaucoma, Pseudoexfoliative Glaucoma, or Ocular Hypertension Naïve to Medical and Surgical Therapy, Treated With Two Trabecular Micro-bypass Stents (iStent Inject) or Travoprost","status":"COMPLETED","sponsor":"Glaukos Corporation","startDate":"2011-09","conditions":"Open-angle Glaucoma","enrollment":196},{"nctId":"NCT02873806","phase":"PHASE4","title":"Two Trabecular Micro-bypass Stents & Postoperative Travoprost to Treat Glaucoma Subjects on Two Hypotensive Agents","status":"COMPLETED","sponsor":"Glaukos Corporation","startDate":"2013-03","conditions":"Open-angle Glaucoma","enrollment":53},{"nctId":"NCT04461249","phase":"","title":"Comparison Between Latanoprost , Travoprost and Tafluprost in Reducing IOP Fluctuation in POAG Patients","status":"COMPLETED","sponsor":"Kasr El Aini Hospital","startDate":"2019-06-01","conditions":"Primary Open Angle Glaucoma","enrollment":60},{"nctId":"NCT03965052","phase":"PHASE1","title":"Safety and Tolerability of the Ophthalmic Solution PRO-179 Compared With Travatan®","status":"COMPLETED","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2019-04-24","conditions":"Glaucoma","enrollment":24},{"nctId":"NCT03966560","phase":"PHASE4","title":"Choroidal Thickness and Its Correlations With Ocular Parameters in Primary Open-angle Glaucoma","status":"COMPLETED","sponsor":"Afyon Kocatepe University Hospital","startDate":"2014-01","conditions":"Glaucoma, Open-Angle","enrollment":96},{"nctId":"NCT02730871","phase":"PHASE4","title":"Safety and Efficacy of SIMBRINZA® BID as an Adjunctive to DUOTRAV®","status":"TERMINATED","sponsor":"Alcon Research","startDate":"2016-06-24","conditions":"Open-angle Glaucoma, Ocular Hypertension","enrollment":173},{"nctId":"NCT00440011","phase":"PHASE4","title":"Bimatoprost 0.03% Versus Travoprost 0.004% in Patients Currently on Latanoprost 0.005%","status":"COMPLETED","sponsor":"Allergan","startDate":"2006-08","conditions":"Glaucoma, Ocular Hypertension","enrollment":266},{"nctId":"NCT00539526","phase":"PHASE4","title":"Evaluation of Hyperemia With the Use of Ocular Prostaglandin Analogues","status":"COMPLETED","sponsor":"Allergan","startDate":"2007-09","conditions":"Open Angle Glaucoma, Ocular Hypertension","enrollment":106},{"nctId":"NCT03150160","phase":"PHASE4","title":"Additive Effect of Twice-daily Brinzolamide 1%/Brimonidine 0.2%Combination as an Adjunctive Therapy to Travoprost in Patients With Normal Tension Glaucoma","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2017-09-21","conditions":"Glaucoma","enrollment":1},{"nctId":"NCT02419508","phase":"PHASE4","title":"SIMBRINZA® Suspension BID as an Adjunctive to Prostaglandin Analogue (PGA)","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2015-08-07","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":290},{"nctId":"NCT01927406","phase":"PHASE4","title":"The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients.","status":"WITHDRAWN","sponsor":"Stanford University","startDate":"2014-06","conditions":"Thyroid Eye Disease, Ocular Hypertension, Glaucoma","enrollment":""},{"nctId":"NCT01443988","phase":"PHASE4","title":"Subjects With Open-angle Glaucoma, Pseudoexfoliative Glaucoma, or Ocular Hypertension Naïve to Medical and Surgical Therapy, Treated With Two Trabecular Micro-bypass Stents (iStent)or Travoprost","status":"COMPLETED","sponsor":"Glaukos Corporation","startDate":"2011-09","conditions":"Open-angle Glaucoma","enrollment":101},{"nctId":"NCT01535768","phase":"PHASE4","title":"Effect of Prophylactic Aqueous Suppression on Hyperencapsulation of Ahmed Glaucoma Valves","status":"UNKNOWN","sponsor":"Credit Valley EyeCare","startDate":"2012-02","conditions":"Glaucoma","enrollment":150},{"nctId":"NCT01298687","phase":"PHASE2","title":"Divided Dose of TRAVATAN®","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2011-02","conditions":"Open-angle Glaucoma, Ocular Hypertension","enrollment":67},{"nctId":"NCT01315574","phase":"PHASE4","title":"Effects of Anti-Glaucoma Medications on the Ocular Surface","status":"TERMINATED","sponsor":"Massachusetts Eye and Ear Infirmary","startDate":"2011-02","conditions":"Glaucoma","enrollment":14},{"nctId":"NCT00759239","phase":"PHASE4","title":"Phase IV Randomised Double-masked Clinical Trial: Assessing Morning Versus Evening Dosing of a Fixed Dose Combination of Travoprost 0.004% / Timolol Maleate 0.5% in Patients With Primary Open-angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2008-09","conditions":"Open-angle Glaucoma, Ocular Hypertension","enrollment":36},{"nctId":"NCT01230736","phase":"PHASE4","title":"Safety and Efficacy of Changing to DuoTrav From Prior Therapy","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2010-10","conditions":"Glaucoma","enrollment":105},{"nctId":"NCT00519753","phase":"PHASE4","title":"Success of Transitioning Uncontrolled Glaucoma Patients From Prior Mono or Adjunctive Therapy to DuoTrav","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2007-08","conditions":"Glaucoma","enrollment":522},{"nctId":"NCT01474135","phase":"PHASE2","title":"AR-12286 Fixed Dose Combination to Lower Elevated Intraocular Pressure","status":"COMPLETED","sponsor":"Aerie Pharmaceuticals","startDate":"2011-12","conditions":"Glaucoma, Ocular Hypertension","enrollment":93},{"nctId":"NCT02003391","phase":"PHASE4","title":"Efficacy of Travoprost/Timolol for Uncontrolled Intraocular Pressure","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2013-12","conditions":"Open Angle Glaucoma, Ocular Hypertension","enrollment":157},{"nctId":"NCT01658839","phase":"PHASE1","title":"Pharmacokinetic and Safety Study of Travoprost 0.004% in Pediatric Glaucoma Patients","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2013-01","conditions":"Glaucoma, Ocular Hypertension","enrollment":25},{"nctId":"NCT00705757","phase":"PHASE4","title":"The Effects of Xalatan, Travatan and Lumigan on Skin Pigmentation Near the Eye","status":"COMPLETED","sponsor":"Summa Health System","startDate":"2008-03","conditions":"Glaucoma, Application Site Pigmentation Changes","enrollment":89},{"nctId":"NCT02097719","phase":"PHASE4","title":"Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2014-05","conditions":"Glaucoma, Ocular Hypertension","enrollment":100},{"nctId":"NCT02140060","phase":"PHASE2","title":"6-Week Proof-of-Concept Study of Travoprost/Brinzolamide Ophthalmic Suspension in Subjects With Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2014-06","conditions":"Glaucoma, Ocular Hypertension","enrollment":327},{"nctId":"NCT01881126","phase":"PHASE4","title":"An Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2013-06","conditions":"Glaucoma, Ocular Hypertension","enrollment":93},{"nctId":"NCT01995136","phase":"PHASE4","title":"Investigation of Intraocular Pressure (IOP) Reduction Efficacy of Travoprost Ophthalmic Solution in Patients With Normal Tension Glaucoma","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2013-09","conditions":"Normal Tension Glaucoma, Ocular Hypertension","enrollment":32},{"nctId":"NCT01664039","phase":"PHASE4","title":"An Efficacy and Tolerability Study of TRAVATAN® Versus LUMIGAN®","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2012-09","conditions":"Glaucoma, Ocular Hypertension","enrollment":104},{"nctId":"NCT01652664","phase":"PHASE3","title":"Study of Travoprost Ophthalmic Solution, 0.004% Compared to Timolol (0.5% or 0.25%) in Pediatric Glaucoma Patients","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2012-09","conditions":"Pediatric Glaucoma, Elevated IOP in Pediatric Patients, Ocular Hypertension in Pediatric Patients","enrollment":184},{"nctId":"NCT01937299","phase":"PHASE4","title":"Effect of SIMBRINZA® Suspension as an Added Therapy to TRAVATAN Z®","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2013-10","conditions":"Ocular Hypertension, Open Angle Glaucoma","enrollment":307},{"nctId":"NCT01514721","phase":"PHASE4","title":"Efficacy of Changing to DuoTrav® (Travoprost 0.004%/Timolol 0.5% BAK-Free Fixed Combination) From Prior Therapy","status":"TERMINATED","sponsor":"Alcon Research","startDate":"2012-06","conditions":"Glaucoma","enrollment":37},{"nctId":"NCT01547598","phase":"PHASE4","title":"Safety and Efficacy of LUMIGAN® RC Versus DuoTrav® in Patients Who Require Further Intraocular Pressure (IOP) Reduction","status":"COMPLETED","sponsor":"Allergan","startDate":"2011-12","conditions":"Glaucoma, Open-Angle, Ocular Hypertension","enrollment":135},{"nctId":"NCT00465803","phase":"PHASE3","title":"A Phase IIIb Study of DuoTrav to Treat Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2007-03","conditions":"Open-angle Glaucoma, Ocular Hypertension","enrollment":81},{"nctId":"NCT00760539","phase":"PHASE3","title":"Safety and Efficacy of Travoprost/Timolol BAC-free","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2008-06","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":87},{"nctId":"NCT00672997","phase":"PHASE3","title":"A Phase III Study of Travoprost/Timolol Combination in Patients With Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2008-05","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":301},{"nctId":"NCT00670033","phase":"PHASE2","title":"Travoprost New Formulations in Patients With Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2008-04","conditions":"Ocular Hypertension, Open-angle Glaucoma","enrollment":158},{"nctId":"NCT01510145","phase":"PHASE4","title":"Efficacy of Changing to TRAVATAN® From Prior Therapy","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2012-02","conditions":"Open-angle Glaucoma, Ocular Hypertension","enrollment":191},{"nctId":"NCT01493427","phase":"PHASE4","title":"Efficacy of Changing to TRAVATAN® From Prior Therapy","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2011-12","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":202},{"nctId":"NCT01789736","phase":"PHASE2","title":"A Study Assessing PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components for 28 Days","status":"COMPLETED","sponsor":"Aerie Pharmaceuticals","startDate":"2013-02","conditions":"Open Angle Glaucoma, Ocular Hypertension","enrollment":234},{"nctId":"NCT01327599","phase":"PHASE4","title":"Efficacy of Changing to DUOTRAV® From Prior Therapy","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2011-08","conditions":"Open-Angle Glaucoma, Ocular Hypertension, Pigment Dispersion Glaucoma","enrollment":60},{"nctId":"NCT01978015","phase":"PHASE4","title":"Blood-aqueous Barrier Changes After the Use of Timolol and Prostaglandin Analogues Fixed Combination in Pseudophakic Patients With POAG","status":"COMPLETED","sponsor":"University of Campinas, Brazil","startDate":"2011-10","conditions":"Uveitis, Anterior, Cystoid Macular Edema","enrollment":69},{"nctId":"NCT01453855","phase":"PHASE3","title":"Travoprost 3-Month Safety and Efficacy Study","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2011-11","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":1099},{"nctId":"NCT01464424","phase":"PHASE4","title":"Assessment of Intraocular Pressure (IOP) Control in Subjects With Open-Angle Glaucoma or Ocular Hypertension Treated With Travoprost 0.004% (TRAVATAN® Z) or Bimatoprost 0.01% (LUMIGAN®)","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2011-10","conditions":"Glaucoma, Ocular Hypertension, Open-Angle Glaucoma","enrollment":84},{"nctId":"NCT00047554","phase":"","title":"Study of TRAVATAN in Subjects With Iris Pigmentation Changes","status":"TERMINATED","sponsor":"Alcon Research","startDate":"2003-05","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":336},{"nctId":"NCT01485822","phase":"","title":"A Multicenter Study of the Pigmentation in the Trabecular Meshwork After Two Years of Treatment With TRAVATAN 0.004% Ophthalmic Solution","status":"TERMINATED","sponsor":"Alcon Research","startDate":"2004-07","conditions":"Open-angle Glaucoma","enrollment":88},{"nctId":"NCT01253902","phase":"PHASE4","title":"Ocular Surface Tolerability Study of Prostaglandin Analogues in Patients With Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2010-12","conditions":"Glaucoma, Open-Angle, Ocular Hypertension","enrollment":164},{"nctId":"NCT01655758","phase":"PHASE4","title":"24-hour Control of Intraocular Pressure (IOP) in Ocular Hypertension","status":"COMPLETED","sponsor":"University of Parma","startDate":"2002-01","conditions":"Ocular Hypertension","enrollment":61},{"nctId":"NCT00690794","phase":"PHASE3","title":"Travatan Z in Ocular Surface Health in Patients With Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2008-07","conditions":"Open-angle Glaucoma, Ocular Hypertension","enrollment":726},{"nctId":"NCT00508469","phase":"PHASE4","title":"Adherence Assessment With Travalert Dosing Aid","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2007-10","conditions":"Open-angle Glaucoma, Ocular Hypertension","enrollment":102},{"nctId":"NCT00966940","phase":"PHASE4","title":"Efficacy and Safety of Travoprost 0.004% Versus Tafluprost 0.0015% in Patients With Primary Open-angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2009-09","conditions":"Glaucoma","enrollment":51},{"nctId":"NCT00798759","phase":"PHASE4","title":"Examination of Ocular Surface Effects With Administration of Travatan Z and XALATAN","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2008-12","conditions":"Open-angle Glaucoma, Ocular Hypertension","enrollment":236},{"nctId":"NCT00676637","phase":"","title":"Glaucoma Adherence Study","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2008-05","conditions":"Ocular Hypertension, Primary Open Angle Glaucoma","enrollment":55},{"nctId":"NCT00680329","phase":"","title":"Glaucoma Adherence Study, Spain","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2008-05","conditions":"Ocular Hypertension, Primary Open Angle Glaucoma","enrollment":55},{"nctId":"NCT00527592","phase":"PHASE4","title":"A Single Dose Comfort Comparison of Travatan Z in One Eye Versus Xalatan in the Opposite Eye in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2007-05","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":54},{"nctId":"NCT00761319","phase":"PHASE3","title":"Phase III Clinical Trial of TRAVATAN Z in Ocular Surface Health","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2008-10","conditions":"Open-angle Glaucoma, Ocular Hypertension","enrollment":705},{"nctId":"NCT00708422","phase":"PHASE4","title":"Effects of Travatan Z and Xalatan on Ocular Surface Health","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2008-07","conditions":"Glaucoma, Ocular Hypertension","enrollment":231},{"nctId":"NCT00848536","phase":"PHASE3","title":"Efficacy Study of Travoprost APS Versus TRAVATAN","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2009-03","conditions":"Open Angle Glaucoma, Ocular Hypertension","enrollment":371},{"nctId":"NCT00311389","phase":"PHASE3","title":"A 12-Month Study to Evaluate the Efficacy and Safety of Once-Daily Instillation of Combination Glaucoma Therapy in Patients With Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2003-01","conditions":"Glaucoma, Open-angle, Ocular Hypertension","enrollment":408},{"nctId":"NCT00293800","phase":"PHASE3","title":"A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2004-07","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":173},{"nctId":"NCT00293787","phase":"PHASE3","title":"A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2004-06","conditions":"Open-angle Glaucoma, Ocular Hypertension","enrollment":156},{"nctId":"NCT01452009","phase":"PHASE3","title":"Three Month Safety and Efficacy Study of TRAVATAN® Versus Travoprost Ophthalmic Solution, 0.004%","status":"WITHDRAWN","sponsor":"Alcon Research","startDate":"2011-11","conditions":"Open Angle Glaucoma, Ocular Hypertension","enrollment":""},{"nctId":"NCT00799682","phase":"PHASE4","title":"Exploratory Study Comparing Signs and Symptoms in Patients With Ocular Hypertension or Glaucoma Using Xalatan R® or Travatan Z®","status":"COMPLETED","sponsor":"Ophthalmic Consultants of Long Island","startDate":"2008-10","conditions":"Dry Eye Disease","enrollment":56},{"nctId":"NCT00471380","phase":"PHASE4","title":"A Phase IV Study of Travoprost + Brinzolamide to Treat Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2007-03","conditions":"Glaucoma, Ocular Hypertension","enrollment":46},{"nctId":"NCT00763061","phase":"PHASE4","title":"Travatan Versus Timoptic in Treating Open-angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2006-05","conditions":"Glaucoma","enrollment":111},{"nctId":"NCT00121147","phase":"NA","title":"Additivity Study: Additive Effect on Eye Pressure of Azopt and Alphagan P to Travatan","status":"COMPLETED","sponsor":"Hermann Eye Center","startDate":"2003-09","conditions":"Open Angle Glaucoma, Ocular Hypertension, Pseudoexfoliation Syndrome","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":11,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Travatan","TRAVATAN®","TRAVATAN Z","TRAVATAN","TRAVATAN Z®"],"phase":"marketed","status":"active","brandName":"Travoprost 0.004% ophthalmic solution","genericName":"Travoprost 0.004% ophthalmic solution","companyName":"Kasr El Aini Hospital","companyId":"kasr-el-aini-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Travoprost is a prostaglandin F analog that binds to prostaglandin F (FP) receptors in the eye to increase uveoscleral outflow of aqueous humor, thereby lowering intraocular pressure. Used for Open-angle glaucoma, Ocular hypertension.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}